A Phase 4 interventional study of Naproxen Sodium (Aleve, BAY117031) and Ibuprofen (Advil) in Pain, Postoperative, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2019-07-18.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing naproxen in Pain, Postoperative — 2 open to participants now, 2 under way, 1 of them phase 3. Naproxen · Pain, Postoperative.
Among the 13 studies testing naproxen in Pain, Postoperative, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 4, and was the 7th registered.
5,662 studies on the registry are indexed under Pain, Postoperative; 1,238 are open to participants now.
Browse Pain, Postoperative studies →2 of the 13 studies testing naproxen in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:
Rothman Institute Orthopaedics · Sites in United States
Ages 18+ · Healthy volunteers
Rothman Institute Orthopaedics · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 328 (48%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 16 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6 · Phase 4 4
First in 2008; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 387 is above the median of 75 across 4,841 interventional studies indexed under Pain, Postoperative.
Median enrollment 200 across the 13 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 7 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 5 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing naproxen in Pain, Postoperative, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the duration of analgesic efficacy as determined by the time to rescue medication of a single oral dose of naproxen sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo over 24 hours in subjects experiencing moderate to severe post-impaction surgery dental pain.
To compare the overall analgesic effect (SPID 0-24) of a single dose of naproxen sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo.
To compare the overall relief from pain (TOTPAR 0-24) of a single dose of naproxen sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received one single dose of 440 mg naproxen sodium tablets (200 mg x 2 tablets, oral) after randomization
Drug: Naproxen Sodium (Aleve, BAY117031)
Participants received one single dose of 400 mg ibuprofen tablets (200 mg x 2 tablets, oral) after randomization
Drug: Ibuprofen (Advil)
Participants received one single dose of matching placebo tablets (2 tablets, oral) after randomization
Drug: Placebo
220 mg x 2 tablets, oral, single dose
200 mg x 2 tablets, oral, single dose
Matching placebo, 2 tablets, oral, single dose
Time to First Use of Rescue Medication
Time to first use of rescue medication was estimated using Kaplan-Meier method. If a subject did not take the rescue medication during the treatment period, (s)he was censored at the time of last assessment.
Time frame: Up to 24 hours
Sum of Pain Intensity Difference (SPID)
Pain intensity was measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each postdose time point, pain intensity differences (PIDs) were derived by subtracting the pain intensity at the postdose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference was indicative of improvement. Time-weighted sum of pain intensity differences (SPIDs) were calculated by multiplying the PID score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values.
Time frame: Up to 24 hours
Total Pain Relief (TOTPAR)
Pain relief was measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values.
Time frame: Up to 24 hours
The study was conducted at one center in the United States, between 12 February 2018 (first patient first visit) and 10 July 2018 (last patient last visit).
| Milestone | Naproxen Sodium (Aleve, BAY117031) | Ibuprofen (Advil) | Placebo |
|---|---|---|---|
| Started | 166 | 166 | 55 |
| Completed | 162 | 164 | 55 |
| Not completed | 4 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 1 | 0 |
Time to first use of rescue medication was estimated using Kaplan-Meier method. If a subject did not take the rescue medication during the treatment period, (s)he was censored at the time of last assessment.
| hours | Naproxen Sodium (Aleve, BAY117031) | Ibuprofen (Advil) | Placebo |
|---|---|---|---|
| Minimum | 1.22 | 1.22 | 1.18 |
| 25th Percentile | 11.017 | 8.267 | 2.117 |
| 50th Percentile | NA | 10.533 | 2.533 |
| 75th Percentile | NA | 14.117 | 12.100 |
| Maximum | 22.17 | 18.28 | 21.75 |
Pain intensity was measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each postdose time point, pain intensity differences (PIDs) were derived by subtracting the pain intensity at the postdose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference was indicative of improvement. Time-weighted sum of pain intensity differences (SPIDs) were calculated by multiplying the PID score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values.
| Scores on a scale * hours | Naproxen Sodium (Aleve, BAY117031) | Ibuprofen (Advil) | Placebo |
|---|---|---|---|
| Sum of Pain Intensity Difference (SPID) | 83.29 ± 57.177 | 48.54 ± 40.705 | 9.96 ± 58.197 |
Pain relief was measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values.
| Scores on a scale * hours | Naproxen Sodium (Aleve, BAY117031) | Ibuprofen (Advil) | Placebo |
|---|---|---|---|
| Total Pain Relief (TOTPAR) | 47.16 ± 28.228 | 28.96 ± 21.097 | 13.40 ± 23.328 |
Collected over From start of study drug up to 10 days after the administration of study drug. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naproxen Sodium (Aleve, BAY117031) | 0/166 (0%) | 1/166 (0.6%) | 25/166 (15.1%) |
| Placebo | 0/55 (0%) | 0/55 (0%) | 16/55 (29.1%) |
| Ibuprofen (Advil) | 0/166 (0%) | 0/166 (0%) | 31/166 (18.7%) |
| Event | Naproxen Sodium (Aleve, BAY117031) | Placebo | Ibuprofen (Advil) |
|---|---|---|---|
| AppendicitisInfections and infestations | 1/166 | 0/55 | 0/166 |
| Event | Naproxen Sodium (Aleve, BAY117031) | Placebo | Ibuprofen (Advil) |
|---|---|---|---|
| NauseaGastrointestinal disorders | 9/166 | 11/55 | 17/166 |
| VomitingGastrointestinal disorders | 1/166 | 7/55 | 7/166 |
| HeadacheNervous system disorders | 3/166 | 7/55 | 6/166 |
| DizzinessNervous system disorders | 4/166 | 1/55 | 5/166 |
| Alveolar osteitisInfections and infestations | 4/166 | 0/55 | 1/166 |
| Abdominal pain upperGastrointestinal disorders | 0/166 | 1/55 | 0/166 |
| ConstipationGastrointestinal disorders | 0/166 | 1/55 | 0/166 |
| PyrexiaGeneral disorders | 0/166 | 1/55 | 1/166 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/166 | 1/55 | 0/166 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/166 | 0/55 | 0/166 |
Safety Population (included all subjects who were randomized and took at least one dose of investigational product)
| Age, Continuous(years) | Naproxen Sodium (Aleve, BAY117031) | Ibuprofen (Advil) | Placebo | Total |
|---|---|---|---|---|
| Mean | 19.0 ± 2.96 | 19.0 ± 2.62 | 19.0 ± 2.91 | 19.0 ± 2.80 |
| Sex: Female, Male(Participants) | Naproxen Sodium (Aleve, BAY117031) | Ibuprofen (Advil) | Placebo | Total |
|---|---|---|---|---|
| Female | 77 | 89 | 30 | 196 |
| Male | 89 | 77 | 25 | 191 |
| Ethnicity (NIH/OMB)(Participants) | Naproxen Sodium (Aleve, BAY117031) | Ibuprofen (Advil) | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 23 | 25 | 10 | 58 |
| Not Hispanic or Latino | 143 | 141 | 45 | 329 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Naproxen Sodium (Aleve, BAY117031) | Ibuprofen (Advil) | Placebo | Total |
|---|---|---|---|---|
| White | 148 | 148 | 48 | 344 |
| Black or African American | 2 | 4 | 1 | 7 |
| American Indian or Alaska Native | 3 | 4 | 2 | 9 |
| Asian | 1 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 3 | 1 | 5 |
| Other | 11 | 5 | 2 | 18 |
| Pain Intensity Score(Participants) | Naproxen Sodium (Aleve, BAY117031) | Ibuprofen (Advil) | Placebo | Total |
|---|---|---|---|---|
| No Pain (0) | 0 | 0 | 0 | 0 |
| Mild Pain (1) | 0 | 0 | 0 | 0 |
| Moderate Pain (2) | 69 | 67 | 23 | 159 |
| Severe Pain (3) | 97 | 99 | 32 | 228 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2018 to primary completion in Jul 2018, 4 months.
Results were first posted in Jul 2019, 1 year after primary completion.
Of 542 phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen